阿尔茨海默病防治策略或需转向:作者呼吁重视血管机制与扩血管药物老药新用
Data suggest a shift in the approach to Alzheimer’s disease prevention and treatment is warranted
David Irwin 在 npj Dementia 发表评论指出,阿尔茨海默病(AD)研究长期聚焦淀粉样蛋白假说但疗效不佳、副作用明显且关键数据遭质疑,应转向血管收缩与高血压机制。
Alzheimer’s Disease (AD) is affecting millions of aging people in the USA and around the world. Especially in the USA, intense efforts have been directed towards developing drugs that might address the Amyloid Hypothesis. But these efforts have proved to be disappointing, with poor efficacy and serious side effects. Moreover, questions continue to be raised regarding the validity of key published data. This approach has largely undervalued the possible contribution of vasoconstriction and hypertension to AD onset and progression. There are many safe drugs currently used to treat hypertension, but their possible relevance to prevent or treat AD has received little attention. There are data in medical records and in clinical trials already documented that indicate vasodilator drugs might have a preventive or even therapeutic role in treating AD. If cheap, already approved drugs were shown to be effective, the implications for healthcare costs could be enormous.
For more than three decades, Alzheimer’s Disease (AD) has defied enormous efforts to develop any meaningful therapeutic interventions1. The common approach is to focus on the Amyloid Hypothesis and attempt to develop drugs that attack or prevent Amyloid-Beta (AB) plaque formation and ensuing neurodegeneration. The recent revelations of data manipulations in some landmark publications implicating AB in memory loss associated with AD raise questions as to whether this focus is fully justified2. Once again, attention is drawn to the poor progress in our understanding of, and drug development for, this devastating disease. Particularly in the USA, little attention has been paid to alternative mechanisms such as vasoconstriction and glymphatic impairment as primary driver of AD. This, despite excellent research suggesting that vascular dysfunction might be a key trigger preceding amyloid build-up3. Indeed, a review commissioned by the journal, Lancet, in the UK, determined that “antihypertensive treatment for hypertension is the only known effective medication for dementia”4. Moreover, a study of close to 34,000 people in China5 showed that lowering blood pressure reduced dementia risk significantly. Surprisingly, there is currently little reference in the general public media to the fact that AD is clearly linked to hypertension.
Closely related to vascular involvement, the more recently described glymphatic system appears to have a role in the clearance of waste from the brain and is very likely involved in the etiology of several degenerative diseases6.
If vasoconstriction in the brain is a significant or primary cause of AD onset, we ought to be able to get a preliminary indication of its relevance and impact by examining anonymized subsets of the medical records of the tens of thousands of patients taking vasodilator drugs. The retrospective meta-analyses of Wolozin7,8 and Barthold9,10 have already begun this approach to search for more compelling evidence to indicate whether such patients are at a lower risk of developing AD (and other dementias), or if it develops later in life when compared to controls not taking vasodilators.
Two key questions are:
Do hypertensive patients on long-term regimens of vasodilator drugs have a lower incidence/higher age onset of AD and other dementias?
What fraction of patients were taking vasodilator drugs before their dementias were diagnosed?
The cited retrospective analyses clearly show a tantalizing association between the use of vasodilator drugs and reduced incidence and degree of neurodegeneration. But the analyses have many confounding factors such as the use of other drugs and the presence of other comorbidities in the patient populations. Preventive clinical trials are notoriously difficult to carry out. The participant study group should be apparently healthy, at least with respect to the disease in question. And, in order to secure approval of a proposed trial, there should be only very minor potential side effects. There are many vasodilator drugs already in common use with only minor side effects that would be candidates for further investigation. But clinical trials are very expensive, and pharmaceutical companies have little interest in testing established, cheap, out-of-patent-protection drugs in off-label applications. Such trials usually need non-profit foundations and NIH support. But what if the pharmaceutical companies already pursuing trials of their latest candidate drugs could be encouraged to add an arm to the trial that would test the most promising vasodilators? The results could be groundbreaking.
In the field of medicine today, we have many examples of how a class of drugs developed for one application subsequently are found to be effective for other very different diseases. The family of semaglutide drugs developed for diabetes is having dramatic effects in treating obesity. The tuberculosis vaccine, BCG, is now used to cure certain malignancies. And anti-inflammatory drugs have been shown to prevent some cancers.
What if modest doses of vasodilators were found to delay onset or reduce symptoms of AD and other dementias? Simply delaying onset by just a few years would have an enormous impact on health care costs, aside from providing significant improvements in the quality of life of the elderly.
Data availability
No datasets were generated or analyzed during the current study.
References
Reiss, A. B. et al. J. Investig. Med. 6, 1135–1140 (2020).
Elliott, C. Science 387, 724 (2025).
Govinpani, K. et al. J. Clin. Med. 8, 651–727 (2019).
Livingston, G. et al. Lancet 396, 413–446 (2020).
He, J. et al. Nat. Med. 31, 2054–2061 (2025).
Smith, J. E. Science 390, 968–970 (2025).
Wolozin, B. Discov. Med. 91, 47–52 (2014).
Li, N.-C. et al. BMJ. 340, b5465 (2026).
Van Dalen, J. W. et al. Neurology 96, e67–e80 (2021).
Gray, S. L. et al. JAMA Netw Open. 9, e2559113 (2026).
Author information
Authors and Affiliations
St. Jude Children’s Research Hospital, Memphis, TN, USA
David Irwin
Authors
- David Irwin
Contributions
The sole author is David Irwin, who is responsible for all searching, drafting, and finalizing. No other authors contributed to this submission.
Corresponding author
Correspondence to David Irwin.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Irwin, D. Data suggest a shift in the approach to Alzheimer’s disease prevention and treatment is warranted. npj Dement. 2, 101 (2026). https://doi.org/10.1038/s44400-026-00154-z
Received: 10 December 2025
Accepted: 28 September 2026
Published: 04 November 2026
Version of record: 04 November 2026
DOI: https://doi.org/10.1038/s44400-026-00154-z
来源:Nature 健康护理主题 · nature.com